Intersect ENT has agreed to acquire Fiagon AG Medical Technologies – Click here to learn more

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years
Novel navigation technology and recently FDA-cleared sinuplasty balloon expand Intersect ENT’s commercial product portfolio Extends Intersect ENT’s footprint in U.S. and European ENT physicians’ offices MENLO PARK, Calif. and BERLIN --(BUSINESS WIRE)--Sep. 15, 2020-- Intersect ENT, Inc.
View HTML
Toggle Summary Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 4, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the second quarter ended June 30, 2020 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 22, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release second quarter 2020 financial results on August 4, 2020 .
View HTML
Toggle Summary Intersect ENT Announces Independent Analysis in UK Confirming Cost Effectiveness of PROPEL® Steroid Releasing Sinus Implant Following Sinus Surgery for Chronic Sinusitis
Toggle Summary CMS Approves SINUVA® Sinus Implant for Reimbursement with New C‐Code and Pass‐Through Payment Status
Toggle Summary Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--May 26, 2020-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the William Blair 40 th Annual Growth Stock Conference . The fireside chat will take place on Thursday, June 11, 2020 at 8:00 a.m.
View HTML
Toggle Summary Intersect ENT Reports First Quarter 2020 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--May 11, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the first quarter ended March 31, 2020 .
View HTML
Toggle Summary Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management
MENLO PARK, Calif. --(BUSINESS WIRE)--May 11, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management
View HTML
Toggle Summary Intersect ENT Reschedules Time of First Quarter 2020 Financial Results Conference Call to 4:30 P.M. ET on May 11, 2020
MENLO PARK, Calif. --(BUSINESS WIRE)--May 8, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced the Company has rescheduled a conference call to discuss its first quarter 2020 financial results to 4:30
View HTML